End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9,980 KRW | -2.16% | +7.43% | -1.96% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.96% | 148M | - | ||
+13.73% | 130B | A- | ||
-8.17% | 10.97B | A- | ||
-4.33% | 8.42B | C | ||
+41.80% | 5.57B | B+ | ||
-21.94% | 4.59B | C | ||
+7.81% | 3.42B | C- | ||
-10.26% | 2.73B | B- | ||
-10.29% | 2.08B | - | - | |
-13.58% | 1.92B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A156100 Stock
- Ratings L&K Biomed Ltd.